ATE305461T1 - Olefinische trans-glukokinase-aktivatoren - Google Patents

Olefinische trans-glukokinase-aktivatoren

Info

Publication number
ATE305461T1
ATE305461T1 AT00987392T AT00987392T ATE305461T1 AT E305461 T1 ATE305461 T1 AT E305461T1 AT 00987392 T AT00987392 T AT 00987392T AT 00987392 T AT00987392 T AT 00987392T AT E305461 T1 ATE305461 T1 AT E305461T1
Authority
AT
Austria
Prior art keywords
olefinic
trans
glucocinase
activators
glucocinase activators
Prior art date
Application number
AT00987392T
Other languages
English (en)
Inventor
Wendy Lea Corbett
Ramakanth Sarabu
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE305461T1 publication Critical patent/ATE305461T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/50—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00987392T 1999-12-15 2000-12-12 Olefinische trans-glukokinase-aktivatoren ATE305461T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17078399P 1999-12-15 1999-12-15
PCT/EP2000/012612 WO2001044216A1 (en) 1999-12-15 2000-12-12 Trans olefinic glucokinase activators

Publications (1)

Publication Number Publication Date
ATE305461T1 true ATE305461T1 (de) 2005-10-15

Family

ID=22621235

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00987392T ATE305461T1 (de) 1999-12-15 2000-12-12 Olefinische trans-glukokinase-aktivatoren

Country Status (33)

Country Link
US (1) US6353111B1 (de)
EP (1) EP1242397B1 (de)
JP (1) JP3824936B2 (de)
KR (1) KR100502032B1 (de)
CN (1) CN1185219C (de)
AR (1) AR032752A1 (de)
AT (1) ATE305461T1 (de)
AU (1) AU781029B2 (de)
CA (1) CA2392903C (de)
CO (1) CO5050295A1 (de)
CZ (1) CZ20022412A3 (de)
DE (1) DE60022903T2 (de)
DK (1) DK1242397T3 (de)
ES (1) ES2249322T3 (de)
GC (1) GC0000264A (de)
HK (1) HK1054383B (de)
HR (1) HRP20020514A2 (de)
HU (1) HUP0203753A3 (de)
IL (2) IL150083A0 (de)
JO (1) JO2180B1 (de)
MA (1) MA26855A1 (de)
MX (1) MXPA02005874A (de)
MY (1) MY125484A (de)
NO (1) NO323142B1 (de)
NZ (1) NZ518974A (de)
PE (1) PE20011022A1 (de)
PL (1) PL355815A1 (de)
RU (1) RU2245332C2 (de)
TW (1) TWI262916B (de)
UY (1) UY26483A1 (de)
WO (1) WO2001044216A1 (de)
YU (1) YU41402A (de)
ZA (1) ZA200203829B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
WO2003055482A1 (en) 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
US7410956B2 (en) 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
WO2003080585A1 (en) * 2002-03-26 2003-10-02 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
MXPA05003559A (es) * 2002-10-03 2005-06-03 Novartis Ag (tiazol-2-il)-amida o sulfonamida substituida como activadores de glicocinasa utiles en el tratamiento de diabetes de tipo 2.
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US8080682B2 (en) 2006-08-24 2011-12-20 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
EP1594863A1 (de) * 2003-02-11 2005-11-16 Prosidion Limited Tricyclo-substituierte amid glucokinase-aktivatoren
PT1723128E (pt) 2004-01-06 2013-02-27 Novo Nordisk As Heteroaril-ureias e o seu uso como activadores da glicoquinase
BRPI0507746A (pt) 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
KR20070006816A (ko) * 2004-04-02 2007-01-11 노파르티스 아게 티아졸로피리딘 유도체, 이를 함유하는 제약 조성물 및글루코키나제 매개형 증상의 치료 방법
AU2005229416B2 (en) * 2004-04-02 2009-03-26 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
EA012204B1 (ru) * 2004-04-21 2009-08-28 Прозидион Лимитед Три(цикло)замещённые амидные соединения
UA90264C2 (ru) * 2004-04-21 2010-04-26 Прозидион Лтд. Три(цикло)замещенные амиды, фармацевтическая композиция, способы лечения и профилактики, способ получения соединения
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
JP2008502658A (ja) * 2004-06-17 2008-01-31 ノボ　ノルディスク　アクティーゼルスカブ 肝臓選択的グルコキナーゼ活性化因子の使用
AU2005271016A1 (en) * 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
KR20080024211A (ko) 2005-07-08 2008-03-17 노보 노르디스크 에이/에스 디시클로알킬 우레아 글루코키나제 활성제
NZ564608A (en) 2005-07-09 2009-09-25 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US8106090B2 (en) 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
JP2009514835A (ja) * 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
DK1951658T3 (da) 2005-11-17 2012-10-15 Lilly Co Eli Glucagonreceptorantagonister, fremstilling og terapeutiske anvendelser
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5386350B2 (ja) * 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
US7902248B2 (en) * 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
CN101622231B (zh) 2007-02-28 2013-12-04 艾德维纳斯医疗私人有限公司 作为葡糖激酶激活剂的2，2，2-三取代的乙酰胺衍生物、它们的制造方法和药学应用
MX2009009525A (es) * 2007-03-07 2009-09-16 Kyorin Seiyaku Kk Activador de glucocinasa.
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
ATE513830T1 (de) * 2007-09-21 2011-07-15 Sanofi Aventis Phenothiazin-derivate mit doppelbindung, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
TW200934772A (en) * 2008-01-15 2009-08-16 Lilly Co Eli Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide
EP2236498A4 (de) 2008-01-18 2012-02-22 Astellas Pharma Inc Phenylacetamidderivat
HRP20150842T1 (hr) * 2008-04-28 2015-09-11 Kyorin Pharmaceutical Co., Ltd. Derivati ciklopentilakrilamida
EA018988B1 (ru) 2008-05-16 2013-12-30 Такеда Калифорния, Инк. Активаторы глюкокиназы
WO2010150280A1 (en) 2009-06-22 2010-12-29 Cadila Healthcare Limited Disubstituted benzamide derivatives as glucokinase (gk) activators
MY156175A (en) 2009-07-31 2016-01-15 Cadila Healthcare Ltd Substituted benzamide derivatives as glucokinase (gk) activators
KR100970871B1 (ko) * 2009-11-30 2010-07-20 케이제이알디 (주) 바닥재 어셈블리 및 바닥재의 시공방법
KR101737151B1 (ko) 2009-12-04 2017-05-17 닛산 가가쿠 고교 가부시키 가이샤 2-피리돈 화합물
EP2553086B1 (de) 2010-03-31 2017-04-19 The Scripps Research Institute Umprogrammierung von zellen
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
HUE052574T2 (hu) 2012-07-13 2021-05-28 Oncternal Therapeutics Inc Eljárás mellrákok kezelésére szelektív ösztrogén receptor modulátorral (SARM)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
EP2921489B1 (de) 2012-11-13 2017-09-06 Nissan Chemical Industries, Ltd. 2-pyridon-verbindung
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
AU2019287437A1 (en) 2018-06-12 2020-09-10 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CN116194442A (zh) 2020-06-08 2023-05-30 维特卫治疗有限责任公司 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的盐或共晶体及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8909574D0 (en) 1989-04-26 1989-06-14 Ici Plc Chemical process
US5169951A (en) 1990-04-23 1992-12-08 Ciba-Geigy Corporation Process for preparing nematicidal compositions
US5510478A (en) * 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
CZ301366B6 (cs) * 1999-03-29 2010-02-03 F. Hoffmann-La Roche Ag 2-Fenyl-3-cykloalkylpropionamidová sloucenina, zpusob její prípravy a farmaceutický prostredek s jejím obsahem

Also Published As

Publication number Publication date
AU2365201A (en) 2001-06-25
WO2001044216A1 (en) 2001-06-21
NZ518974A (en) 2004-04-30
HK1054383B (zh) 2005-04-22
KR100502032B1 (ko) 2005-07-25
IL150083A0 (en) 2002-12-01
CN1185219C (zh) 2005-01-19
DE60022903D1 (de) 2006-02-09
AU781029B2 (en) 2005-04-28
JP3824936B2 (ja) 2006-09-20
HUP0203753A2 (hu) 2003-03-28
TWI262916B (en) 2006-10-01
CA2392903A1 (en) 2001-06-21
ZA200203829B (en) 2003-08-14
HRP20020514A2 (en) 2004-06-30
NO20022863D0 (no) 2002-06-14
IL150083A (en) 2010-04-15
MXPA02005874A (es) 2002-10-23
CO5050295A1 (es) 2001-06-27
MY125484A (en) 2006-08-30
JO2180B1 (en) 2003-04-23
CA2392903C (en) 2008-08-05
EP1242397B1 (de) 2005-09-28
CZ20022412A3 (cs) 2002-10-16
PE20011022A1 (es) 2001-10-11
JP2003516980A (ja) 2003-05-20
ES2249322T3 (es) 2006-04-01
GC0000264A (en) 2006-11-01
PL355815A1 (en) 2004-05-17
CN1411453A (zh) 2003-04-16
HK1054383A1 (en) 2003-11-28
KR20020067555A (ko) 2002-08-22
DK1242397T3 (da) 2006-02-13
NO323142B1 (no) 2007-01-08
YU41402A (sh) 2005-07-19
HUP0203753A3 (en) 2004-12-28
EP1242397A1 (de) 2002-09-25
UY26483A1 (es) 2001-06-29
MA26855A1 (fr) 2004-12-20
NO20022863L (no) 2002-06-14
DE60022903T2 (de) 2006-07-06
RU2245332C2 (ru) 2005-01-27
US6353111B1 (en) 2002-03-05
AR032752A1 (es) 2003-11-26

Similar Documents

Publication Publication Date Title
DE60022903D1 (de) Olefinische trans-glukokinase-aktivatoren
DE60014610D1 (de) Glukokinase aktivatoren
DE69912411D1 (de) Olefinpolymerisation
DE60044873D1 (de) Orientierte biopolymermembrane
DE122007000064I1 (de) Erythropoietinkonjugate
DE19983871T1 (de) Fönvorrichtung
DE60134470D1 (de) Para-amin substituierte phenylamid glukokinase activatoren
DE10084676T1 (de) Einmallanzettvorrichtung
DK1311504T3 (da) Tetrazolyl-phenylacetamid-glucokinase-aktivatorer
DE50002834D1 (de) Handstempel
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
DE69921460D1 (de) Olefinpolymerisation
DE50000805D1 (de) Aufsitzspanner
DE10085008T1 (de) Oberflächenbehandlungsdüse
DE50003660D1 (de) Diacylhydrazinderivate
DE50006013D1 (de) Anschlagpuffer
DE19983890T1 (de) Ventiltaktgebungsjustiereinrichtung
DE50001640D1 (de) Nahfeldoptische untersuchungsvorrichtung
DE50006759D1 (de) Piperidinalkohole
ATE440824T1 (de) Nitro-sulfobenzamide
ATE269311T1 (de) Benzoylpyridazine
DE10082008D2 (de) Ausbeulgerät
EP1174511A4 (de) Promotoren
DE50003283D1 (de) Exzenterspannzwinge

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1242397

Country of ref document: EP

REN Ceased due to non-payment of the annual fee